By Tom Winnifrith and Steve Moore | Sunday 20 February 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
SkinBioTherapeutics (SBTX) has published a “Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Thursday »
Wednesday »
Tuesday »
Monday »
Time left: 21:06:00